HASBROUCK HEIGHTS, N.J., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce that a presentation on NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), will be given during the 28 th Annual European Association of Urology Congress in Milan, Italy 3:45 p.m. March 17. The meeting will be held in the Milano Congressi.
The paper, "Clinical studies of NX-1207: Phase 3 Injectable for BPH," will be presented by Ronald Tutrone Jr, MD, FACS, the Medical Director of the Chesapeake Urology Research Associates of Towson, MD. Dr. Tutrone has participated as an investigator in three of the prospective NX-1207 clinical trials as well as follow-up studies. Dr. Tutrone will present data on NX-1207 and the NX-1207 clinical trials to date, including the two Phase 3 clinical trials currently in progress.
NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials for BPH and Phase 2 for localized prostate cancer. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials where a single dose of NX-1207 has been found to produce on average symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. Follow-up studies have shown evidence of long lasting benefit with a significant proportion of men who received a single dose reporting maintained improvement in BPH symptoms without other treatments for up to 7½ years.NX-1207 is in Phase 3, the last stage before filing with the FDA for approval. NX-1207 is injected by a urologist in an office setting and involves little or no pain or discomfort. For more information about the NX-1207 Phase 3 clinical trials please go to www.clinicaltrials.gov or contact Nymox at email@example.com. More information about Nymox is available at www.nymox.com , email: firstname.lastname@example.org, or 800-936-9669. This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: For Further Information Contact: Brian Doyle Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com